Joseph K. Belanoff MD
Chief Executive Officer, President, and Director
Dr Belanoff is the co-founder of Corcept Therapeutics and has served as a member of the Board and as the Chief Executive Officer since 1999. In 2013, he was also appointed President. Dr Belanoff is currently a clinical faculty member and has held various positions in the Department of Psychiatry and Behavioral Sciences at Stanford University since 1992. Dr Belanoff received his BA from Amherst College and his MD from Columbia University’s College of Physicians & Surgeons.
Andreas Grauer MD
Chief Medical Officer
Dr Grauer joined Corcept as Chief Medical Officer in 2019. He brings nearly 20 years of experience in the pharmaceutical and biotechnology industries. From 2008 to 2019, he worked for Amgen as Executive Medical Director and subsequently as the Vice President Global Development, Therapeutic Area Head for Bone, Nephrology and Inflammation. During his tenure at Amgen, Dr Grauer led a significant number of development programs resulting in multiple successful new drug application (NDA) and biologic license application (BLA) filings. From 2000 to 2007, he was the Executive Medical Director for New Business and Technology Development and the Global Medical Director for Bone at Procter & Gamble Pharmaceuticals. Dr. Grauer received his medical education at the University of Heidelberg in Germany and the Royal Postgraduate Medical School at the Hammersmith Hospital in London, UK and his subsequent clinical training at the University of Heidelberg. He is Board-Certified in both internal medicine and endocrinology in Germany. Dr Grauer has authored more than 100 manuscripts and book chapters in the field of endocrinology and metabolic bone diseases and continues to serve on faculty at the University of Heidelberg Medical School in Germany as an Associate Professor of Medicine.
Hazel Hunt PhD
Chief Scientific Officer
Dr Hunt was named Corcept’s Chief Scientific Officer in 2020. Prior to that she was Senior Vice President, Research at Corcept. Dr. Hunt joined Corcept in 2011, bringing with her more than 23 years of experience in the pharmaceutical and biotechnology industries. From 2002 to 2011, Dr. Hunt was Director of Chemistry and Operations at Argenta, where she worked closely with Corcept and played an integral role in the discovery of Corcept’s portfolio of next-generation selective GR antagonists. From 1994 to 2002, she worked for Celltech, initially as a Group Leader in Medicinal Chemistry and ultimately as Section Leader, Project Chemistry. From 1992 to 1994, she served as a Research Fellow at The Centre for Drug Design and Development. Before that Dr Hunt worked at Glaxo Group Research as a Senior Chemist in Medicinal Chemistry. Dr Hunt received a first-class honors degree in chemistry from the Australian National University and a PhD in synthetic organic chemistry from the University of Southampton, UK. She also carried out postdoctoral work at Oxford University and the University of California at Irvine.
Chief Commercial Officer
Mr Maduck was named Corcept’s Chief Commercial Officer in 2020. Prior to that he was Corcept’s Senior Vice President, Commercial. Before that, he was the company’s Vice President, Sales & Marketing. Mr Maduck joined Corcept in 2012, bringing to the company 12 years of pharmaceutical, biotechnology and management experience. From 2002 to 2012, he held positions in the Finance, Portfolio Planning, and Commercial functions at Genentech. Prior to Genentech, he was an investment banking analyst at W.R. Hambrecht + Company. He currently serves on the Board of Directors of the Cancer Support Community – San Francisco Bay Area. Mr Maduck earned an AB from Dartmouth College, a BE in Biomedical Engineering from the Thayer School of Engineering at Dartmouth College, and a Masters in Management from the Stanford Graduate School of Business.
Chief Financial Officer
Mr Mokari joined Corcept as Chief Financial Officer in March 2021. He brings to the company nearly 20 years leadership experience in life sciences and healthcare finance. From 2018 to 2020, he was Chief Financial Officer and Vice President of Corporate Development at Bellicum Pharmaceuticals, Inc. He served in the same capacity from 2016 to 2018 at medical device manufacturer IRIDEX. Mr. Mokari was a director at Wells Fargo Securities LLC’s healthcare investment banking group from 2013 to 2016, at UBS’s healthcare investment banking group from 2009 to 2013 and at Credit Suisse’s healthcare investment banking group from 2005 to 2009. Prior to that, he was a member of the business development team at Forest Laboratories, a pharmaceutical company, and an analyst at the private equity firm Olympus Partners and the investment banking firm Bowles Hollowell Conner & Co. Mr. Mokari earned an MBA from The Tuck School of Business at Dartmouth and a B.S. in Chemistry and Biology from Duke University.
Chief Business Officer
Mr Robb became Corcept’s Chief Business Officer in March 2021 after serving more than nine years as the company’s Chief Financial Officer. Mr Robb has more than 30 years of experience in executive management, operations and finance. From April 2005 through August 2011, Mr Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc., a fitness equipment and training company with operations in the United States, Europe, and Asia. From 2003 to 2005, Mr Robb was engaged in the private practice of law. From 2000 to 2002, he was Senior Vice President of Citadon, Inc. He also held positions in business development for Nomura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc., from 1996 to 1998. From 1992 to 1996, Mr Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr Robb earned a BA in English and Political Philosophy from Yale and a JD from Harvard Law School, where he was a member of the Harvard Law Review.